Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-23-173982
Filing Date
2023-06-23
Accepted
2023-06-23 17:28:15
Documents
13

Document Format Files

Seq Description Document Type Size
1 S-3 d473990ds3.htm S-3 459022
2 EX-1.2 d473990dex12.htm EX-1.2 193517
3 EX-4.1 d473990dex41.htm EX-4.1 5921
4 EX-4.3 d473990dex43.htm EX-4.3 293941
5 EX-5.1 d473990dex51.htm EX-5.1 26732
6 EX-23.1 d473990dex231.htm EX-23.1 1627
7 EX-23.2 d473990dex232.htm EX-23.2 1749
8 EX-FILING FEES d473990dexfilingfees.htm EX-FILING FEES 82659
9 GRAPHIC g473990dsp003.jpg GRAPHIC 432559
10 GRAPHIC g473990g04a00.jpg GRAPHIC 46931
11 GRAPHIC g473990g0622080255161.jpg GRAPHIC 3252
12 GRAPHIC g473990g0622080255348.jpg GRAPHIC 1414
13 GRAPHIC g473990g08a00.jpg GRAPHIC 74325
  Complete submission text file 0001193125-23-173982.txt   1825648
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-272909 | Film No.: 231038793
SIC: 2834 Pharmaceutical Preparations